AUG 13, 2017 12:52 PM PDT

Experimental Drug Slows Progression of Rare Genetic Disease

WRITTEN BY: Carmen Leitch

Researchers have identified a drug that has slowed the progression of a rare genetic disease in clinical trials. A fatal neurological disorder primarily affecting young people, Niemann-Pick disease type C1 (NPC1) is a degenerative disease in which cognitive and neurological functions progressively decline. The new work has been reported in the Lancet and is described in the following video.

The National Institutes of Health (NIH) is working with Sucampo Pharmaceuticals to cooperate on the development of the new drug, 2-hydroxypropyl-beta-cyclodextrin (VTS-270). A clinical trial compared two groups: one with 14 participants from four to 23 years old who received the drug once a month for 12 to 18 months, and another group of three who got the drug every two weeks for 18 months. Once it was seen that the more frequent doses were well tolerated, doses were increased for the other participants. The results were compared to the progress of patients in a previous study.

“The results are very encouraging and support continued development of VTS-270 for treating NPC1,” said Forbes D. Porter, M.D., Ph.D., clinical director at NIH’s Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) and the study’s senior author. “Compared to untreated patients we followed in an earlier study, participants who received VTS-270 scored better on a scale used to evaluate disease severity and progression, including elements such as speech, cognition, and mobility.”

The drug did not increase adverse outcomes for participants, although some patients with hearing loss did experience more hearing loss after treatment. Hearing aids were used to help these patients, and they could go on with a normal life.

Niemann-Pick disease type C1, a lipid storage disorder, as seen in a mouse cerebellum / Credit: NICHD

NPC1 causes a buildup of cholesterol in brain cells, resulting in the disease symptoms. The investigators thus assessed cholesterol metabolism in the study participants’ central nervous system and found a cholesterol metabolite. That suggested that the drug is improving the cholesterol metabolism dysfunction carried by the patients. The levels of two other molecules indicated that there was likely less damage occurring in the brain as well.

Patient neurological assessments demonstrated that the drug was slowing disease progression. Because of these encouraging results, the scientists are seeking to move on to another clinical trial, already approved by the FDA, to find the symptoms that the drug is targeting, and to refine the dosage. The ultimate goal, of course, is to bring this drug to all NPC1 patients who could benefit from it.

 

Sources: NIH, The Lancet

About the Author
  • Experienced research scientist and technical expert with authorships on 28 peer-reviewed publications, traveler to over 60 countries, published photographer and internationally-exhibited painter, volunteer trained in disaster-response, CPR and DV counseling.
You May Also Like
MAR 22, 2020
Microbiology
MAR 22, 2020
The Benefits of Being a Loner
Outliers exist everywhere in nature, and it seems they serve an important purpose.
MAR 22, 2020
Cell & Molecular Biology
MAR 22, 2020
Capturing Images of Firing Neurons
Our bodies run on electricity. Neurons send rapidly fired electrical signals through the brain and limbs constantly, ena ...
MAR 27, 2020
Genetics & Genomics
MAR 27, 2020
Expanding the Genomic Regions That Can Be Targeted With CRISPR
CRISPR gene-editing technology has sparked a revolution in biomedical research and is poised to have far-reaching applic ...
APR 04, 2020
Cancer
APR 04, 2020
Unique Cancer Mutation Hijacks Nearby Signaling Pathway
  In cancer, tyrosine kinase mutations are quite common. MET is one such example that normally binds its native lig ...
MAY 26, 2020
Cell & Molecular Biology
MAY 26, 2020
The Lasting Glow of Tube Worm Slime
Tube worms are ancient creatures that can be found near hydrothermal vents on the seafloor. Their bioluminescence apears ...
MAY 27, 2020
Cell & Molecular Biology
MAY 27, 2020
A Deeper Understanding of How Some Bacterial Toxins Interact With Cells
The surfaces of cells are decorated with receptors, and the interactions between receptors and their binding partners ar ...
Loading Comments...